Aminoglutethimide and testololactone may be considered the first generation aromatase
inhibitors for the endocrine treatment of breast carcinoma. Initially, both of these agents were …

Anastrozole is a new oral nonsteroidal aromatase inhibitor indicated for the second-line
endocrine treatment of postmenopausal women with advanced breast cancer. In …

Epidermal growth factor receptors (EGFRs) were measured in 221 primary breast cancers
by ligand binding with 125 I-labelled EGF, and high-affinity sites were quantitated. There …

Three steps in the catalytic cycle of cytochrome P450 (P450, CYP; see Chapters 5 and 6)
are particularly vulnerable to inhibition:(a) the binding of substrates,(b) the binding of …

Epidermal growth factor receptors (EGFR) and oestrogen receptors (ER) were analysed in
221 patients with primary operable breast cancer by means of radioligand assays. After …

The catalytic cycle of cytochrome P450 (see Chapters 3 and 8) traverses three steps that are
particularly vulnerable to inhibition:(1) the binding of substrates,(2) the binding of molecular …

Cytochrome P450s (P450s) are subject to inhibition/inactivation by various chemically
diverse agents, which may interact directly or indirectly with either the P450 prosthetic heme …

The catalytic cycle of cytochrome P-450 (see Chapter 7) traverses three steps that are
particularly vulnerable to inhibition:(1) the binding of substrates,(2) the binding of molecular …

About one-third of breast cancers require oestrogen for continued growth and will regress
following oestrogen deprivation(23). This phenomenon provides the rationale behind …

Abstract Synopsis Formestane (4-hydroxyandrostenedione) is an effective and competitive
inhibitor of aromatase, the enzyme responsible for the conversion of androgens to estrone …